Preclinical Testing of Human Ghrelin for the Treatment of Stroke

人生长素释放肽治疗中风的临床前测试

• 批准号: 8777639
• 负责人: Wayne Chaung
• 金额: $ 22.49万
• 依托单位: THERASOURCE, LLC
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8777639
• 关键词: Accounting; Adult; Age; Alteplase; American; Animal Model; Blood - brain barrier anatomy; Blood gas; Brain; Brain Edema; Brain Injuries; Cardiovascular system; Caring; Cause of Death; Cerebral Ischemia; Cerebrovascular Circulation; Cessation of life; Clinical Trials; Continuous Infusion; Cost of Illness; Development; Dose; Drug Industry; Drug Kinetics; Economics; Evaluation; Family; Future; GHS-R1a; Gastrointestinal Hormones; Goals; Impairment; Infarction; Ischemic Stroke; Ligands; Long-Term Effects; Mediating; Medical; Middle Cerebral Artery Occlusion; Morbidity - disease rate; Motor; Nervous System Physiology; Neuraxis; Neurologic; Normal saline; Patients; Peripheral; Phase; Physiological; Population; Preclinical Testing; Prevalence; Rattus; Recurrence; Reperfusion Therapy; Reporting; Role; Serum; Small Business Innovation Research Grant; Societies; Somatotropin; Stroke; Survivors; Therapeutic; Therapeutic Agents; Time; Touch sensation; United States; acute stroke; commercialization; cost; cytokine; disability; dosage; effective therapy; experience; ghrelin; ghrelin receptor; human ghrelin; improved; male; neuron apoptosis; novel; novel therapeutic intervention; novel therapeutics; phase 2 study; pre-clinical; programs; public health relevance; research study; response; social

DESCRIPTION (provided by applicant): The ultimate objective of this program is to develop a novel therapeutic approach that will save lives of patients with stroke. Acute stroke is the third leading cause of death in the United States and the primary medical cause of acquired adult disability. Each year, ~795,000 Americans experience new or recurrent stroke. It accounts for 1 out of every 18 deaths in the United States. As the population ages, stroke care costs are expected to increase substantially. The direct medical costs for stroke care are estimated to increase from $28.3 billion in 2010 to $95.6 billion in 2030. Despite its prevalence, current treatment options are very limited and stroke survivors still encounter serious morbidity issues. The development of safe and effective therapeutics to treat stroke patients remains a major challenge to the pharmaceutical industry. Human ghrelin, a novel gastrointestinal hormone, was first identified as the endogenous ligand for the growth hormone secretagogue receptor type 1a (i.e., ghrelin receptor). Ghrelin freely crosses the blood brain barrier (BBB) and has been reported to induce growth hormone release through stimulation of ghrelin receptor in the central nervous system. However, sufficient evidence has pointed out other physiological functions of ghrelin in addition to its role in growth hormone release. Using an animal model of permanent middle cerebral artery occlusion (i.e., ischemic stroke), our preliminary studies have shown that human ghrelin treatment improved neurological function, reduced infarct size, and increased survival. The primary objective of this project is targeted towards demonstrating the feasibility o the further development and commercialization of human ghrelin as a novel therapeutic agent for stroke patients. Animal models of ischemic stroke with or without reperfusion will be used. The optimal dosage(s) and therapeutic window will be determined by assessing the dose-dependent effect of human ghrelin on brain injury and the time-course of human ghrelin's beneficial effects after stroke. Furthermore, we will investigate the long-term effect of human ghrelin on motor function impairment after ischemic stroke with or without reperfusion. Our future goal (SBIR Phase II and beyond) is to obtain commercial utilization of human ghrelin as a safe and effective therapy for patients suffering from stroke.

描述（由申请人提供）：该项目的最终目标是开发一种新的治疗方法，以挽救中风患者的生命。急性中风是美国第三大死亡原因，也是获得性成人残疾的主要医学原因。每年约有795，000美国人经历新发或复发性中风。它占美国每18例死亡中的1例。随着人口老龄化，中风护理费用预计将大幅增加。中风护理的直接医疗费用估计将从2010年的283亿美元增加到2030年的956亿美元。尽管其流行，目前的治疗选择是非常有限的，中风幸存者仍然遇到严重的发病率问题。开发安全有效的治疗中风患者的疗法仍然是制药行业面临的主要挑战。人生长激素释放肽是一种新的胃肠道激素，首先被鉴定为生长激素促分泌素受体1a型（即，生长激素释放肽受体）。Ghrelin可自由穿过血脑屏障（BBB），并据报道通过刺激中枢神经系统中的Ghrelin受体诱导生长激素释放。然而，有足够的证据指出，除了生长激素释放的作用，生长激素释放肽的其他生理功能。使用永久性大脑中动脉闭塞的动物模型（即，缺血性中风）时，我们的初步研究已经表明，人生长素释放肽治疗改善了神经功能，减小了梗死面积，并增加了存活率。该项目的主要目的是证明进一步开发和商业化人ghrelin作为中风患者的新型治疗药物的可行性。将使用有或无再灌注的缺血性卒中动物模型。最佳剂量和治疗窗将通过评估人生长素释放肽对脑损伤的剂量依赖性作用和中风后人生长素释放肽有益作用的时间过程来确定。此外，我们将研究长期的影响，人类生长激素释放肽对运动功能障碍后，缺血性中风有或没有再灌注。我们未来的目标（SBIR II期及以后）是获得人类生长激素释放肽的商业利用，作为一种安全有效的治疗中风患者。